Arthritis patients experience referral delays, audit finds
August 18, 2016
Great Hope for Immunotherapy
August 18, 2016
Show all

Gilead Sales of Hepatitis C Drugs Fall 19%

Multiple hepatitis C medications now available are affecting prices.

Gilead Sciences Inc. said its revenue from its hepatitis C drugs continued to fall, dropping 19% during the second quarter, with sales of Harvoni missing expectations as competition from rival drugs and pricing pressures intensified.

Shares of the company slipped 3% to $85.90 after hours.

The Foster City, Calif., biopharmaceutical company also lowered its 2016 product sales outlook to $29.5 billion to $30.5 billion, from its previous estimate for products sales of $30 billion to $31 billion.

For the latest quarter, Gilead reported Harvoni sales decreased 29% to $2.56 billion, while Sovaldi sales rose 5.2% to $1.36 billion. Analysts had expected Harvoni sales of $2.87 billion and Sovaldi sales of $1.19 billion, according to FactSet.

The company also said its recently approved combination hepatitis C drug, Epclusa, which is priced lower than the older hepatitis C treatments, generated sales of $64 million.

Read Full Article: Gilead Sales of Hepatitis C Drugs Fall 19%

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.